On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Analysts are cautious, having chopped their estimates for fourth-quarter earnings growth to 1.5% from the previous year - or ...

Find insight on Novo Nordisk Foundation, ResMed, Johnson & Johnson, and more in the latest Market Talks covering Health Care.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Nvidia stock is higher Tuesday after President Trump revoked a 2023 executive order targeting AI developers. Here's what we ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...